Peptide Romania
performance

Ipamorelin

Selective ghrelin-receptor agonist examined for GH release with minimal cortisol effect.

Dovezi
Moderate
T½
~2 h
Categorie
performance
Status
Investigational

Evaluarea dovezilor

Baza de dovezi

Moderate66%

Strong: Multiple studii umane controlate cu rezultate consistente și replicate de grupuri independente de cercetare.

Moderate: Studii umane sau animale cu semnale pozitive; există variabilitate metodologică sau date conflictuale limitate.

Emerging: Cercetare timpurie, predominant preclinică, cu rezultate promițătoare. Confirmarea umană este limitată.

Preliminary: Date foarte limitate, în principal rapoarte exploratorii sau studii singulare fără replicare independentă.

Farmacologie

Mecanism de acțiune

Selective ghrelin-receptor agonist examined for GH release with minimal cortisol effect.

T½~2 h
StatusInvestigational
Categorieperformance
DoveziModerate

Întrebări frecvente

Ce trebuie să știi

Selective ghrelin-receptor agonist examined for GH release with minimal cortisol effect.
Ipamorelin has Moderate evidence. Human or animal studies show positive signals, but some methodological variation or conflicting data exists. Further large-scale trials are needed to confirm findings.
The half-life of Ipamorelin is ~2 h. This determines dosing frequency in research protocols — shorter half-lives require more frequent administration to maintain stable concentrations in study subjects.
Ipamorelin is currently classified as: Investigational. Regulatory status varies by jurisdiction — always consult local regulations and a qualified medical professional before any use outside an approved clinical context.
Selective ghrelin-receptor agonist examined for GH release with minimal cortisol effect.
Înapoi la peptide